At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 21, 2026 at 17:30 ET
Zymeworks announced positive Phase 1 data for ZW191, an FRα-targeting antibody-drug conjugate, showing a 61% confirmed objective response rate in platinum-resistant ovarian cancer at doses of 6.4–9.6 mg/kg, with durable responses and a manageable safety profile. The data support advancing ZW191 into later-stage development for ovarian and endometrial cancers, where treatment options are limited.
- ZW191 showed a 61% confirmed objective response rate (cORR) in platinum-resistant ovarian cancer at 6.4–9.6 mg/kg dose range.
- Median progression-free survival was 7.6 months; median duration of response not reached, indicating durability.
- Activity was observed regardless of FRα expression, expanding potential patient population.
- Safety profile was manageable, with 55% grade ≥3 treatment-emergent adverse events (mostly neutropenia, anemia, thrombocytopenia).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access